Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:
Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)
Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)
CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)
Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)
Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av,
eller tillsammans med, Poddtoppen.